Meet us at COP31 · Startup Zone, Antalya, 9 to 20 NovemberRead more
Shanghai Fosun Pharmaceutical (Group) Co Ltd 2025 Annual Report
Company: Shanghai Fosun Pharmaceutical (Group) Co Ltd
Sector: Manufacturing
Country: China
Year: 2025
Type: Annual Report
Pages: 295
The report describes the company's 2025 revenue of RMB41,498 million and total R&D expenditure of RMB5,913 million. It highlights approvals and launches for innovative drugs in China and international markets, including Serplulimab and Denosumab. The company also reports continued implementation of its AI strategy across R&D, clinical development, production, operations and commercialization.
No standards or assurance data is available for this report.
Indicators available in this report:
No materiality data is available for this report.